myPOS Enables iDEAL Payments Acceptance
30.10.2018 17:00:00 EET | Business Wire | Press release
myPOS is thrilled to announce that it expands the tools available in its online marketplace integration by partnering with iDEAL – an innovative payment solution which allows customers to pay for items and services by directly linking their bank account, circumventing the need for inputting credit card information.
iDEAL is a quick, secure and convenient payment solution from the Netherlands which negates the need for any kind of registration or enrolment. As long as the customer has a bank account with a bank partnered with iDEAL, all they need to do is log in with their online banking details, which automatically completes the transaction in the environment of the bank itself. This ensures that there’s no security risk at all, and is also much quicker and convenient than having to enter your credit card details by hand.
All myPOS clients located in the Netherlands can easily implement iDEAL into their online stores using myPOS APIs. The solution is also available for several marketplaces supported by myPOS, like WooCommerce, OpenCart, Magento and more. While the market availability of iDEAL is limited for the time being, customers within that market will be pleased to have an alternate, easier method of checking out, if they don’t wish for whatever reason to input their credit card details online.
This new development is a big part of myPOS CEO Christo Georgiev’s plan for the future of the company. “The goal of myPOS is to provide an all-in-one solution for small and medium businesses, for both their physical and online storefronts,” said Mr. Georgiev in a statement regarding the integration. “As such we will continue to work hard and add new features on both fronts, to benefit both our clients and their customers.”
About myPOS Europe Ltd
myPOS Europe Ltd is a licensed
payments provider and processor, registered at 25 Canada Square, Level
33, Canary Wharf London E14 5LB, United Kingdom.
The myPOS package includes a smart POS device, free myPOS account with business VISA card and access to additional merchant services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181030005677/en/
Contact information
myPOS Europe Ltd
Irina Stefanova
PR manager
irina.stefanova@mypos.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartsheet Unveils vsActual: The AI-Native Platform that Connects Strategy to Execution at ENGAGE 20264.11.2026 19:00:00 EET | Press release
Smartsheet, the AI-powered enterprise work management platform, today unveiled a new AI-native strategic planning and execution product at ENGAGE 2026, its annual customer conference. vsActual is designed to solve the two biggest obstacles to enterprise execution: siloed work scattered across disconnected systems and teams, and the manual tracking and reporting that keeps individuals and executives from seeing problems until it’s too late. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104989965/en/ Today, Smartsheet unveiled a new AI-native strategic planning and execution product, vsActual. AI is helping individuals move faster than ever, but it's also making it harder to keep everyone moving in the same direction. In fact, a PMI research report found that leaders cited the disconnect between planning and execution as the biggest barrier to reinventing their businesses, and VentureBeat Intelligence found that 64% of res
SES Achieves Optical Communications Milestone for Future meoSphere Network4.11.2026 19:00:00 EET | Press release
SES, in collaboration with leading space technology partners, has successfully demonstrated a bi-directional optical communications link between ground and space through its meoSphere Pathfinder 1 mission, marking an important milestone in the development of the company's next-generation meoSphere network. The achievement validates a critical technology that will support future high-capacity, secure and flexible connectivity services. During the demonstration, SES successfully transmitted video messages from CEO Adel Al-Saleh over a bidirectional optical communications link between Cailabs' optical ground station in Rennes, France, and an SES payload flying on K2’s GRAVITAS mission on their Mega-class satellite platform. The mission utilized a Mynaric CONDOR optical terminal onboard. SES designed, developed, and operated the optical mission and developed automation software that enabled the demonstration. Thales Alenia Space supported system assembly, integration, testing and operation
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom